Vendor Intelligence Report: LiliPeptide

Published 3 Jul 2026. 27-page investigative report on who is behind LiliPeptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

LiliPeptide is not a simple pass/fail vendor. Across 284 Finnrick lab tests, the record is 200 pass / 82 fail for a 70% overall pass rate. GHK-Cu is the standout positive; Retatrutide and Tirzepatide are conditional buys needing current lot proof; TB-500 is the clearest avoid signal. Stricter grading pulls ratings down, so the public figure is an optimistic harm-reduction view, not pharmaceutical assurance.

The identity file is more concerning than the storefront implies. The vendor record lists a U.S. location, but the report found no verified U.S. corporate entity; the strongest artifacts point to a China/Hong Kong footprint: Chinese registrar history, Shoplazza infrastructure, Hong Kong contact numbers and a Chinese registry lead whose geography conflicts with a linked profile trail.

The web network adds channel-confusion risk. The live vendor domain is typo-spelled, the correct-spelling domain sits under Peptide-Sources maintenance, and a sister storefront carries PeptiSlim branding. A privacy-policy artifact ties PeptSlim back into the LiliPeptide orbit, while the primary site has rotated into six new buyer-facing personas instead of the older Bella/xabelle anchor retained elsewhere.

The operational risk is not just non-shipment. Finnrick tests and community receipts show real material can reach buyers. The sharper hazard is post-payment escalation: Trustpilot complaints describe courier or postage demands after checkout, including a $300 extra-postage demand on a low-value parcel and recurring logistics personas. Channel verification and refusing unexpected post-checkout fees become central buyer controls.

Inside the full report:

  • Per-product Finnrick ratings, spark-grid history and methodology-divergence charts for all 12 tested products
  • Domain forensics for lilipetide.com, lilipeptide.com and elitepeptide66.com
  • Corporate-identity review covering Chinese registry leads, Hong Kong contacts and the missing verified U.S. entity
  • PeptSlim/PeptiSlim brand-linkage exhibits, including privacy-policy and sister-storefront captures
  • Trustpilot and Reddit reputation analysis separating fulfillment reports from post-purchase courier-fee complaints
  • Negative findings on Atlas Peptides Lab, reverse-IP expansion and public affiliate promotion scans

Risk assessment

  • Corporate identity and jurisdiction opacity — high: Listed U.S. location is not backed by a verified U.S. entity; records point to Shanghai Meicheng/Shoplazza infrastructure, Hong Kong contacts and a Chinese registry lead.
  • Post-purchase courier-fee extortion risk — high: Trustpilot complaints describe Atlas/courier fee demands after payment, including a $300 extra-postage demand and recurring Monica Kelly/Jenny Chong personas.
  • High product-quality risk in low-performing products — high: TB-500 22.3%, CJC-1295 24.82%, NAD+ 35.41%, plus Tesamorelin 50.8%, MOTS-c 52.15% and Melanotan II 53.14%, are poor LiliPeptide choices without lot-specific proof.
  • Batch-consistency risk in conditional products — medium: Retatrutide 78.45%, Tirzepatide 77.46% and BPC-157 71.18% have real test depth but should be treated as conditional buys requiring lot-specific verification.
  • Brand-confusion and channel-verification risk — medium: Typo primary domain, correct-spelling Peptide-Sources maintenance domain, ElitePeptide66/PeptSlim overlap and rotating personas leave buyers without a clear official-channel or anti-counterfeit path.